Skip to main content
main-content

HBV

Latest articles

15-08-2017 | HBV | News | Article

Serum biomarkers combine to improve HCC risk stratification in HBV patients with low viremia

In patients with persistently low serum levels of hepatitis B virus DNA, the combined use of the noninvasive aspartate aminotransferase to platelet ratio index and the Fibrosis-4 index could help identify those at increased risk for developing hepatocellular carcinoma.

Source:

Liver Int 2017; Advance online publication

15-08-2017 | HBV | News | Article

HCC incidence declines with prolonged HBV treatment

The incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection declines significantly after the first 5 years of treatment with the nucleos(t)ide analogs entecavir and/or tenofovir, researchers report.

Source:

Hepatology 2017; Advance online publication

11-08-2017 | HBV | News | Article

Real-world outcomes of antiviral therapy in Asian chronic HBV patients described

Analysis of a community-based cohort comprising mainly Asian patients receiving antiviral therapy for chronic hepatitis B virus infection shows a higher rate of hepatitis B surface antigen loss than is generally reported for Asian clinical trial cohorts.

04-08-2017 | HBV | News | Article

Anti-HBc levels predict hepatic inflammation in patients with chronic HBV

Serum hepatitis B core antibody levels significantly predict hepatic inflammation in patients with chronic hepatitis B virus infection, including those with normal alanine aminotransferase levels, Chinese research shows.

Source:

Sci Rep 2017; 7: 2747

27-07-2017 | HBV | Highlight | Article

Editor's pick

Maternal HBV infection raises preterm birth risk

Women with hepatitis B virus infection prior to becoming pregnant are significantly more likely to have a preterm birth than those without HBV, shows an analysis of a Chinese population-based cohort.

Source:

Lancet Glob Health 2017; 5: e624–e632, e563–e564

27-07-2017 | HBV | News | Article

Temporal liver cancer trends in HBV-endemic population mapped

A South Korean population-based study shows an increase in liver cancer burden over a 14-year period, while another analysis in the same population shows an improvement in the survival of patients with hepatocellular cancer in the past decade.

Source:

J Gastroenterol Hepatol 2017; Advance online publication, Hepatology 2017; Advance online publication

05-06-2017 | HBV | News | Article

Editor's pick

Overt, occult HBV infection remains a concern despite immunization

Despite a universal program to vaccinate newborns against hepatitis B virus infection, the prevalence of overt and occult infection among children in northwest China is a cause for concern, say researchers.

Source:

J Viral Hepat 2017; Advance online publication

05-06-2017 | HBV | News | Article

Support for TDF in patients with HBV-related decompensated cirrhosis

Among patients with hepatitis B virus-related decompensated cirrhosis, first-line tenofovir disoproxil fumarate therapy not only reduces HBV DNA levels, but also improves hepatic function, indicates a real-world South Korean study.

Source:

World J Gastroenterol 2017; 23: 2396–2403

01-06-2017 | HBV | News | Article

Higher rate of anti-HBs disappearance with recombinant versus plasma HBV vaccine

The infant recombinant yeast hepatitis B virus vaccine has long-term efficacy, but the rate of disappearance of protective antibodies against hepatitis B surface antigen is higher than with the plasma-derived vaccine, shows a study of Taiwanese university students.

Source:

Liver Int 2017; Advance online publication

01-06-2017 | HBV | News | Article

PAGE-B model validated in Asian chronic HBV patients

Korean researchers show that the PAGE-B model for prediction of hepatocellular carcinoma risk has applicability in Asian patients with chronic hepatitis B virus infection treated with entecavir or tenofovir disoproxil fumarate.

Source:

Liver Int 2017; Advance online publication

30-05-2017 | HBV | News | Article

Prolonged TDF monotherapy supported in multidrug-resistant HBV

Treatment with tenofovir disoproxil fumarate alone is efficacious over the long term in patients with chronic hepatitis B virus infection that is resistant to multiple antiviral agents, research indicates.

Source:

Hepatology 2017; Advance online publication

30-05-2017 | HBV | News | Article

Temporal liver stiffness improvements observed during antiviral HBV therapy

Serial liver stiffness measurement is a useful tool for monitoring longitudinal improvements in advanced fibrosis among patients receiving antiviral treatment for chronic hepatitis B virus infection, say researchers.

Source:

Am J Gastroenterol 2017; Advance online publication

07-04-2017 | HBV | News | Article

Tenofovir-based salvage therapy has long-term benefits in chronic hepatitis B

Long-term tenofovir disoproxil fumarate salvage therapy is effective for patients with chronic hepatitis B virus infection who have previously failed to respond to lamivudine and adefovir dipivoxil, 5-year TDF-109 study data show.

Source:

Liver Int 2016; Advance online publication

07-04-2017 | HBV | News | Article

Editor's pick

HBV suppresses hepatic innate immune response

The host hepatic innate immune response is downregulated in untreated patients with chronic hepatitis B virus infection, shows a gene expression analysis.

Source:

J Hepatol 2017; Advance online publication

04-04-2017 | HBV | News | Article

TDF, entecavir efficacy confirmed in real-world HBV cohort

Treatment with a tenofovir disoproxil fumarate-containing regimen or entecavir leads to high virologic and biochemical response rates in patients with chronic hepatitis B virus infection, shows a registry analysis.

Source:

Dig Dis Sci 2017; 62: 784–793

04-04-2017 | HBV | News | Article

Host, viral factors associated with persistently elevated ALT in chronic HBV patients

Hepatic steatosis, hepatitis B e antigen seropositivity, and age are independently associated with persistent increases in serum alanine aminotransferase levels in patients with chronic hepatitis B virus infection receiving antiviral therapy, a study shows.

Source:

Clin Gastroenterol Hepatol 2017; Advance online publication

31-03-2017 | HBV | News | Article

HBV DNA suppression sustained with switch to tenofovir

Italian research shows that patients with chronic hepatitis B virus infection maintain long-term virologic suppression after switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy, with a low rate of adverse events.

Source:

Dig Liver Dis 2017; Advance online publication

31-03-2017 | HBV | News | Article

Low IL-27 levels linked to spontaneous HBeAg seroconversion

Interleukin-27 levels could help identify individuals with chronic hepatitis B virus infection who are likely to achieve hepatitis B e antigen seroconversion in the absence of antiviral treatment, a chart review suggests.

Source:

Liver Int 2017; Advance online publication

10-02-2017 | HBV | News | Article

Liver fibrosis steadily increases in untreated HBV with stable viral load

Liver fibrosis, estimated using the Fibrosis-4 index, increases significantly over time in untreated patients with hepatitis B infection, despite viral loads remaining largely stable, US researchers report.

Source:

J Gastroenterol Hepatol 2016; Advance online publication

09-02-2017 | HBV | News | Article

IFN-λ3 induction shows potential as anti-HBV therapy

Early research from Japan suggests that induction of interferon-λ3 could be a promising therapeutic strategy in patients with hepatitis B virus infection.

Source:

Gut 2016; Advance online publication

image credits